TY - JOUR
T1 - CTCF deletion syndrome
T2 - Clinical features and epigenetic delineation
AU - Hori, Ikumi
AU - Kawamura, Rie
AU - Nakabayashi, Kazuhiko
AU - Watanabe, Hidetaka
AU - Higashimoto, Ken
AU - Tomikawa, Junko
AU - Ieda, Daisuke
AU - Ohashi, Kei
AU - Negishi, Yutaka
AU - Hattori, Ayako
AU - Sugio, Yoshitsugu
AU - Wakui, Keiko
AU - Hata, Kenichiro
AU - Soejima, Hidenobu
AU - Kurosawa, Kenji
AU - Saitoh, Shinji
N1 - Publisher Copyright:
© Article author(s) 2017. All rights reserved.
PY - 2017/12/1
Y1 - 2017/12/1
N2 - Background Heterozygous mutations in CTCF have been reported in patients with distinct clinical features including intellectual disability. However, the precise pathomechanism underlying the phenotype remains to be uncovered, partly because of the diverse function of CTCF. Here we describe extensive clinical and genetic investigation for two patients with a microdeletion encompassing CTCF. Methods We performed genetic examination including comprehensive investigation of X chromosome inactivation and DNA methylation profiling at imprinted loci and genome-wide. Results Two patients showed comparable clinical features to those in a previous report, indicating that haploinsufficiency of CTCF was the major determinant of the microdeletion syndrome. Despite the haploinsufficiency of CTCF, X chromosome inactivation was normal. DNA methylation at imprinted loci was normal, but hypermethylation at CTCF binding sites was demonstrated, of which PRKCZ and FGFR2 were identified as candidate genes. Conclusions This study confirms that haploinsufficiency of CTCF causes distinct clinical features, and that a microdeletion encompassing CTCF could cause a recognisable CTCF deletion syndrome. Perturbed DNA methylation at CTCF binding sites, not at imprinted loci, may underlie the pathomechanism of the syndrome.
AB - Background Heterozygous mutations in CTCF have been reported in patients with distinct clinical features including intellectual disability. However, the precise pathomechanism underlying the phenotype remains to be uncovered, partly because of the diverse function of CTCF. Here we describe extensive clinical and genetic investigation for two patients with a microdeletion encompassing CTCF. Methods We performed genetic examination including comprehensive investigation of X chromosome inactivation and DNA methylation profiling at imprinted loci and genome-wide. Results Two patients showed comparable clinical features to those in a previous report, indicating that haploinsufficiency of CTCF was the major determinant of the microdeletion syndrome. Despite the haploinsufficiency of CTCF, X chromosome inactivation was normal. DNA methylation at imprinted loci was normal, but hypermethylation at CTCF binding sites was demonstrated, of which PRKCZ and FGFR2 were identified as candidate genes. Conclusions This study confirms that haploinsufficiency of CTCF causes distinct clinical features, and that a microdeletion encompassing CTCF could cause a recognisable CTCF deletion syndrome. Perturbed DNA methylation at CTCF binding sites, not at imprinted loci, may underlie the pathomechanism of the syndrome.
UR - http://www.scopus.com/inward/record.url?scp=85037042841&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85037042841&partnerID=8YFLogxK
U2 - 10.1136/jmedgenet-2017-104854
DO - 10.1136/jmedgenet-2017-104854
M3 - Article
C2 - 28848059
AN - SCOPUS:85037042841
SN - 0022-2593
VL - 54
SP - 836
EP - 842
JO - Journal of Medical Genetics
JF - Journal of Medical Genetics
IS - 12
ER -